样本量估算错误对ARDS试验解读的影响:系统评价与荟萃分析
该系统评价与荟萃分析纳入1994年美国欧洲共识会议ARDS定义后开始招募、2020年10月31日前发表的150项ARDS随机对照试验,仅84项(56.0%)报告了样本量估算。以死亡率为主要终点的试验中,28项有16项(57.1%)高估了对照事件率;要达到预测的平均治疗效应,干预需预防40.8%的全部死亡,而原始预测为29.3%;绝对死亡率下降≥10%在28项中仅5项(17.9%)观察到,但28项中21项(75.0%)曾预测到。观察到的对照事件率与观察到的平均治疗效应之间无关联(汇总OR:β=-0.04;95%可信区间,-0.18至0.09)。作者认为贝叶斯方法可用于优先排序未来有效性随机对照试验的干预措施。
要点
- 150项ARDS随机对照试验中仅84项(56.0%)报告了样本量估算,报告不一致且对照事件率和平均治疗效应设定错误常见。
- 以死亡率为主要终点的28项试验中,16项(57.1%)高估了对照事件率;要达到预测平均治疗效应需预防40.8%的全部死亡,而原始预测为29.3%。
- 绝对死亡率下降≥10%在28项中仅5项(17.9%)观察到,但28项中21项(75.0%)曾预测到。
- 以死亡率为主要终点的试验中,观察到的对照事件率与观察到的平均治疗效应无关联(汇总OR:β=-0.04;95%可信区间,-0.18至0.09)。
- 三种目前非标准治疗的干预(糖皮质激素、气道压力释放通气、无创通气)贝叶斯平均效应量>0.20且现有证据强度中等。
适用人群与场景
- 1994年美国欧洲共识会议ARDS定义后开始招募、2020年10月31日前发表的ARDS随机对照试验。
研究设计与关键结果
- 系统评价与荟萃分析纳入150项ARDS随机对照试验,仅84项(56.0%)报告了样本量估算。
- 以死亡率为主要终点的28项随机对照试验中,16项(57.1%)高估了对照事件率。
- 以死亡率为主要终点的随机对照试验中,要达到预测的平均治疗效应,干预需预防40.8%的全部死亡,而原始预测为29.3%。
- 绝对死亡率下降≥10%在28项随机对照试验中仅5项(17.9%)观察到,但28项中21项(75.0%)曾预测到。
- 以死亡率为主要终点的随机对照试验中,观察到的对照事件率与观察到的平均治疗效应无关联(汇总OR:β=-0.04;95%可信区间,-0.18至0.09)。
- 三种目前非标准治疗的干预(糖皮质激素、气道压力释放通气、无创通气)贝叶斯平均效应量>0.20且现有证据强度中等。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,采用贝叶斯平均荟萃分析、试验序贯分析和贝叶斯因子量化证据强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于全因死亡率的ARDS随机对照试验预后富集策略不太可能成功。
- 作者认为,贝叶斯方法可用于优先排序未来有效性随机对照试验的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Indeterminate randomized controlled trials (RCTs) in ARDS may arise from sample size misspecification, leading to abandonment of efficacious therapies.
RESEARCH QUESTIONS: If evidence exists for sample size misspecification in ARDS RCTs, has this led to rejection of potentially beneficial therapies? Does evidence exist for prognostic enrichment in RCTs using mortality as a primary outcome?
STUDY DESIGN AND METHODS: We identified 150 ARDS RCTs commencing recruitment after the 1994 American European Consensus Conference ARDS definition and published before October 31, 2020. We examined predicted-observed sample size, predicted-observed control event rate (CER), predicted-observed average treatment effect (ATE), and the relationship between observed CER and observed ATE for RCTs with mortality and nonmortality primary outcome measures. To quantify the strength of evidence, we used Bayesian-averaged meta-analysis, trial sequential analysis, and Bayes factors.
RESULTS: Only 84 of 150 RCTs (56.0%) reported sample size estimations. In RCTs with mortality as the primary outcome, CER was overestimated in 16 of 28 RCTs (57.1%). To achieve predicted ATE, interventions needed to prevent 40.8% of all deaths, compared with the original prediction of 29.3%. Absolute reduction in mortality ≥ 10% was observed in 5 of 28 RCTs (17.9%) but was predicted in 21 of 28 RCTs (75.0%). For RCTs with mortality as the primary outcome, no association was found between observed CER and observed ATE (pooled OR: β = -0.04; 95% credible interval, -0.18 to 0.09). We identified three interventions that are not currently standard of care with a Bayesian-averaged effect size of > 0.20 and moderate strength of existing evidence: corticosteroids, airway pressure release ventilation, and noninvasive ventilation.
INTERPRETATION: Reporting of sample size estimations was inconsistent in ARDS RCTs, and misspecification of CER and ATE was common. Prognostic enrichment strategies in ARDS RCTs based on all-cause mortality are unlikely to be successful. Bayesian methods can be used to prioritize interventions for future effectiveness RCTs.
参考来源
- Saha R, Assouline B, Mason G, et al. The Impact of Sample Size Misestimations on the Interpretation of ARDS Trials: Systematic Review and Meta-analysis. Chest. 2022. PMID: 35643115. doi:10.1016/j.chest.2022.05.018
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。